Clinomics is a leading company in the early diagnosis of cancer/other diseases based on genomics and aims to overcome aging and diseases through liquid biopsies and multi-omics technology. Clinomics specializes in offering a genome-based, early cancer diagnostic service through technology for multi-omics analysis and simultaneous detection of CTC and cfDNA in the blood based on its internationally renowned biomedical information processing abilities. Furthermore, Clinomics is a biotechnology company with leading technology for genome editing based on its unrivaled genomic technology. As a precision medicine company leading the field of personalized medicine, we offer various solutions for customized precision medicine based on our core values of challenge, innovation, integrity and communication. We are releasing a variety of products through consistent research and development. Clinomics will become key to a healthy and happy future for humanity through its liquid biopsy and multi-omics analysis technology.